Shionogi & Co., Ltd. (TYO:4507) Logo
Shionogi & Co., Ltd. (TYO:4507) symbol, logo with name and high resolution download options.
About Shionogi & Co., Ltd. (TYO:4507)
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer������s disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. It has a research and license option agreement with BioVersys AG to develop novel ansamycin leads from BV500 program into clinical candidates. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
Get Shionogi & Co., Ltd. (TYO:4507) Logo via API
Integrate this logo into your application with a single API call
Why Use Our Stock Logo API?
Fast Delivery
<100ms response time via global CDN
Enterprise-Ready
99.99% uptime SLA with GDPR compliance
Multiple Formats
SVG, PNG, WebP - scalable to any size
400k+ Logos
Stocks, ETFs, Crypto, Banks, and more
Where to Use Stock Logos
Trading Platforms
Real-time stock displays with instant logo loading
Portfolio Apps
Visualize holdings with recognizable brand logos
Financial Dashboards
Enhance market data with company branding
News & Research
Illustrate articles with accurate company logos
Frequently Asked Questions
Need Stock Logos for Your Application?
Access 380,000+ company logos via our simple REST API. Perfect for trading platforms, portfolio apps, and financial dashboards.